gefitinib has been researched along with prx 08066 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (prx 08066) | Trials (prx 08066) | Recent Studies (post-2010) (prx 08066) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 5 | 0 | 4 |
| Protein | Taxonomy | gefitinib (IC50) | prx 08066 (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.1368 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Maksoud, MS; Ali, EMH; Oh, CH | 1 |
1 review(s) available for gefitinib and prx 08066
| Article | Year |
|---|---|
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Chemistry, Pharmaceutical; Humans; Inflammation; Neoplasms; Pyrimidines; Structure-Activity Relationship | 2019 |